BIT:1BMRN - Euronext Milan - US09061G1013 - Common Stock - Currency: EUR
BIT:1BMRN (5/19/2025, 7:00:00 PM)
52.36
-9.36 (-15.17%)
The current stock price of 1BMRN.MI is 52.36 EUR.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
4AB.DE | ABBVIE INC | 18.1 | 288.98B | ||
AMG.DE | AMGEN INC | 13.39 | 131.60B | ||
GIS.DE | GILEAD SCIENCES INC | 14.08 | 119.42B | ||
VX1.DE | VERTEX PHARMACEUTICALS INC | N/A | 100.90B | ||
1REGN.MI | REGENERON PHARMACEUTICALS | 13.82 | 58.22B | ||
ARGX.BR | ARGENX SE | 108.39 | 31.17B | ||
22UA.DE | BIONTECH SE-ADR | N/A | 20.94B | ||
IDP.DE | BIOGEN INC | 8.14 | 16.61B | ||
0QF.DE | MODERNA INC | N/A | 9.21B | ||
1MRNA.MI | MODERNA INC | N/A | 8.79B | ||
BIO.DE | BIOTEST AG | 65.85 | 1.69B | ||
GLPG.AS | GALAPAGOS NV | N/A | 1.69B |
BioMarin Pharmaceutical, Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. The company is headquartered in Novato, California and currently employs 3,401 full-time employees. BioMarin's commercial products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Palynziq (pegvaliase-pqpz), Brineura (cerliponase alfa), Aldurazyme (laronidase), Roctavian (valoctocogene roxaparvovec), Kuvan (sapropterin dihydrochloride), and Voxzogo (vosoritide). Vimizim is an enzyme replacement therapy for the treatment of MPS IVA, a lysosomal storage disorder. The Roctavian is an adeno associated virus (AAV5) vector gene therapy designed to restore factor VIII plasma concentrations in patients with severe hemophilia A. Voxzogo is a once daily injection analog of C-type Natriuretic Peptide (CNP) for the treatment of achondroplasia. Brineura is a recombinant human tripeptidyl peptidase 1 (TPP1) for the treatment of patients with CLN2, a form of Batten disease.
BIOMARIN PHARMACEUTICAL INC
105 Digital Drive
Novato CALIFORNIA US
Employees: 3401
Phone: 14155056700
The current stock price of 1BMRN.MI is 52.36 EUR. The price decreased by -15.17% in the last trading session.
The exchange symbol of BIOMARIN PHARMACEUTICAL INC is 1BMRN and it is listed on the Euronext Milan exchange.
1BMRN.MI stock is listed on the Euronext Milan exchange.
35 analysts have analysed 1BMRN.MI and the average price target is 93.14 EUR. This implies a price increase of 77.88% is expected in the next year compared to the current price of 52.36. Check the BIOMARIN PHARMACEUTICAL INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
BIOMARIN PHARMACEUTICAL INC (1BMRN.MI) has a market capitalization of 9.98B EUR. This makes 1BMRN.MI a Mid Cap stock.
BIOMARIN PHARMACEUTICAL INC (1BMRN.MI) currently has 3401 employees.
The Revenue of BIOMARIN PHARMACEUTICAL INC (1BMRN.MI) is expected to grow by 17.05% in the next year. Check the estimates tab for more information on the 1BMRN.MI EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
1BMRN.MI does not pay a dividend.
BIOMARIN PHARMACEUTICAL INC (1BMRN.MI) will report earnings on 2025-02-20, after the market close.
The PE ratio for BIOMARIN PHARMACEUTICAL INC (1BMRN.MI) is 34. This is based on the reported non-GAAP earnings per share of 1.54 and the current share price of 52.36 EUR. Check the full fundamental report for a full analysis of the valuation metrics for 1BMRN.MI.
ChartMill assigns a technical rating of 1 / 10 to 1BMRN.MI.
ChartMill assigns a fundamental rating of 6 / 10 to 1BMRN.MI. While 1BMRN.MI has a great health rating, its profitability is only average at the moment.
Over the last trailing twelve months 1BMRN.MI reported a non-GAAP Earnings per Share(EPS) of 1.54. The EPS increased by 127.27% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | 11.71% | ||
ROA | 4.7% | ||
ROE | 5.95% | ||
Debt/Equity | 0.11 |
ChartMill assigns a Buy % Consensus number of 79% to 1BMRN.MI. The Buy consensus is the average rating of analysts ratings from 35 analysts.
For the next year, analysts expect an EPS growth of 120.5% and a revenue growth 17.05% for 1BMRN.MI